Skip to main content

Cowen Raises Sage Value On New Phase 2 Trial Success

By: via Benzinga
SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.